Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook [Yahoo! Finance]
Akoya BioSciences, Inc. (AKYA)
Company Research
Source: Yahoo! Finance
Revenue estimates were cut sharply as the analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well. After this downgrade, Akoya Biosciences' seven analysts are now forecasting revenues of US$99m in 2025. This would be a notable 14% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$116m in 2025. The consensus view seems to have become more pessimistic on Akoya Biosciences, noting the substantial drop in revenue estimates in this update. See our latest analysis for Akoya Biosciences The consensus price target fell 19% to US$3.88, with the analysts clearly less optimistic about Akoya Biosciences' valuation following this update. One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's pretty clear that there is an expectation that Akoya Bio
Show less
Read more
Impact Snapshot
Event Time:
AKYA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKYA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKYA alerts
High impacting Akoya BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
AKYA
News
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions [Yahoo! Finance]Yahoo! Finance
- Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment DecisionsGlobeNewswire
- Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone [Yahoo! Finance]Yahoo! Finance
- Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry MilestoneGlobeNewswire
- Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
AKYA
Earnings
- 11/14/24 - Miss
AKYA
Sec Filings
- 12/13/24 - Form 8-K
- 11/21/24 - Form 4
- 11/21/24 - Form 4
- AKYA's page on the SEC website